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Several antithrombotic strategies have been tested to reduce this high residual cardiovascular risk: (i) replacing aspirin with another antiplatelet drug (clopidogrel, 3 terutroban, 4 or ticagrelor 5 ); (ii) adding another antiplatelet drug to aspirin (clopidogrel, 6 vorapaxar, 7 6 Vorapaxar (a PAR-1 blocker) added to aspirin and/or clopidogrel was shown to reduce serious vascular events in patients with a history of atherosclerotic vascular disease, but with a significant increase in the risk of intracerebral haemorrhage and other major bleeding, particularly in those with a history of ischaemic stroke, so that benefits appeared to be confined to subgroups with prior MI or peripheral artery disease (PAD) without a history of stroke. 7 Among patients who had had MI 1-3-years previously, the combination of ticagrelor and aspirin resulted in a lower rate of major vascular events and a higher rate of major bleeding than aspirin alone, and there was no significant between-group difference in mortality. 8 Finally, long-term treatment with a vitamin K antagonist, alone or in combination with aspirin, was shown superior to aspirin for secondary prevention after acute MI but was associated with more bleeding, including intracranial bleeding. 9 It should be emphasized that nation-wide registry data during the past 20 years showed marked reductions in mortality and in the incidence of cardiovascular outcomes, 10 as reflected by the 50% drop in the annual rate of major vascular events recorded in the aspirin-treated arm from 5.8% in the CAPRIE trial 3 to 3.0% in the PEGASUS trial. 8 Within this context, the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial was designed to test the hypothesis that rivaroxaban (a direct factor Xa inhibitor: 2.5 mg bid) in combination with low-dose aspirin (100 mg once daily) or given alone (5.0 mg bid) is more effective than aspirin alone in preventing recurrent vascular events in patients with stable atherosclerotic vascular disease. 11 Patients were eligible, if they met the criteria for coronary artery disease (CAD), PAD, or both. Out of a total of 27 395 persons who were randomized to receive one of the three antithrombotic regimens, 91% had a history of CAD, and 27% had a history of PAD (with about 4% also having a history of stroke). The mean age of participants was 68 years, and 70-90% received blood pressure-and/or lipid-lowering agents. The primary efficacy outcome was the composite of cardiovascular death, stroke, or MI. The main safety outcome was a modification of the International Society on Thrombosis and Haemostasis (ISTH) criteria for major bleeding. Unlike the ISTH criteria, the COMPASS Investigators considered all bleeding that led to presentation to an acute care facility or hospitalization as major. 11 The study was stopped prematurely for superiority of combination therapy vs. aspirin alone after a mean followup of 23 months. Thus, at the first planned interim analysis (50% of planned efficacy outcomes), the independent data and safety monitoring board recommended early termination of the randomized comparison of rivaroxaban with or without aspirin vs. aspirin alone, having observed a consistent difference in the primary efficacy outcome in favour of rivaroxaban plus aspirin. 11 A primary outcome event occurred in 379 patients (4.1%) who were assigned to rivaroxaban plus aspirin, 448 (4.9%) who were assigned to rivaroxaban alone, and 496 (5.4%) who were assigned to aspirin alone. For the comparison of rivaroxaban plus aspirin vs. aspirin alone, the hazard ratio (HR) for the primary outcome was 0.76 (95% confidence interval [CI], 0.66-0.86; P < 0.001). The benefits of combination therapy (largely driven by a reduction in ischaemic stroke and cardiovascular death) appeared early and continued to accrue over time. For the comparison of rivaroxaban alone vs. aspirin alone, the HR was 0.90 (95% CI, 0.79-1.03; P = 0.12). There were 313 deaths (3.4%) in the combined therapy group as compared with 378 (4.1%) in the aspirin alone group (HR = 0.82; 95% CI, 0.71-0.96; P = 0.01; threshold P-value for significance, 0.0025). Major bleeding events occurred in more patients in the rivaroxaban plus aspirin group (3.1%) than in the aspirin alone group (1.9%) (HR = 1.70; 95% CI, 1.40-2.05; P < 0.001), mainly due to a difference in bleeding that led to presentation to an acute care facility or hospitalization. Most of the excess major bleeding was into the gastrointestinal tract, with no significant between-group difference in the rate of fatal bleeding, intracranial bleeding, or symptomatic bleeding into a critical organ. 11 Whether upper gastrointestinal bleeding (UGIB) is reduced by a proton-pump inhibitor (PPI) in this setting is currently being examined in an ongoing randomized comparison of pantoprazole with placebo in patients participating in the trial who were not receiving a PPI. Strengths of the COMPASS trial are represented by its large sample size and statistical robustness of its main finding as well as by its consistency in both CAD and PAD patients. Weaknesses include early termination of the trial which may over-estimate the treatment effect as well as reduce the statistical power to detect differences in the less frequent but more severe forms of bleeding, and the fact that only aspirin-tolerant patients at low-to-moderate haemorrhagic risk were included.
Mechanistically, selective factor Xa inhibition and platelet cyclooxygenase (COX)-1 inactivation appear equally effective in preventing major vascular events in stable patients with CAD or PAD, a concept reinforced by the early termination due to futility of the NAVIGATE-ESUS trial, a head-to-head comparison of rivaroxaban (15 mg once daily) vs. low-dose aspirin in 7000 patients with a recent embolic stroke of undetermined source. These interesting findings may help rethink the pathophysiology of vascular complications in these different clinical settings.
The results of COMPASS should be viewed in the context of other pharmacologic strategies aimed at addressing residual cardiovascular risk in a similar setting ( Table 1) . These include targeting the platelet P2Y 12 receptor with ticagrelor, 8 proprotein convertase subtilisin-kexin type 9 (PCSK9) with evolocumab, 12 or interleukin-1b with kanakinumab. 13 All these strategies proved effective in reducing the composite outcome of serious vascular events by 15-24%, with variable effects on mortality, in 90-100% aspirin-treated, stable patients whose annual rate of major vascular events ranged from 2.8% to 4.5%. The absolute benefits ranged between 4 and 7 vascular events prevented per 1000 patients treated for 1 year, with a number-needed-to-treat (NNT) ranging between 143 and 250. Costeffectiveness considerations, the different spectrum of side-effects, as well as the availability of long-term safety data of these interventions will determine the extent of their implementation in clinical practice. In perspective, although it would seem conceptually desirable to compare the addition to aspirin of a second antiplatelet drug vs. a factor Xa inhibitor, or substituting a P2Y 12 inhibitor for aspirin in combination with a factor Xa inhibitor, 14 one should consider the exponential increase in NNT values associated with progressively smaller absolute benefits that might realistically result from head-to-head comparisons of effective antithrombotic regimens in patients with an expected vascular event rate of about 3.0% per year. Perhaps, more pragmatically, efforts should be redirected towards reducing the burden of UGIB complications associated with combined antithrombotic strategies through the appropriate use of PPIs, particularly in the elderly, 15 and improving the utilization of evidence-based lipid-lowering and anti-hypertensive treatments of proven long-term safety. CVD, cardiovascular disease; CANTOS, canakinumab antiinflammatory thrombosis outcomes study; COMPASS, cardiovascular outcomes for people using anticoagulation strategies; FOURIER, further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk; PEGASUS-TIMI 54, prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in MI 54.
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